Prevail Therapeutics Inc. (NASDAQ:PRVL) changes shares on Tuesday trading session, with a change of -1.97% or -$0.31 shares. The trading starts at $15.89 and closed at $15.75 throughout the day. The trading session low price was $15.26 and day high was $15.89 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.12 million while its average volume is 184.69K. In other hand, the PRVL market cap reached to $516.78M. While, its current target price is $22.14.
On March 26, 2020, BRIEF-Prevail Therapeutics Reports Full Year 2019 Financial Results And Business Highlights. According to the news reported on Reuters, * PREVAIL THERAPEUTICS REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -3.68% and up 0.19% for month. Its quarterly performance was -1.22% below, while its half year performance is down -18.65%. PRVL yearly performance stood at positive 47.33% and fall -2.46% for year-to-date. Current recommendation for Prevail Therapeutics Inc. is 1.40.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. PRVL EPS (TTM) for 12-month is -3.13. EPS for this year is -295.00%, while for the next year its value is -2.37. Its EPS Q/Q reached -90.90%. It has an EPS of next five years will be up 4.90%.
Let’s take a look on the analyst recommendations on PRVL for the current month and previous month. For the current month, 8 of 8 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 0 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $20.00 – $25.00. Average target price for PRVL was reached at $22.14.
Orbimed Advisors LLC., RA Capital Management, L.P. and EcoR1 Capital, LLC are the top three holders in Prevail Therapeutics Inc. (PRVL) stock. On Mar 30, 2020, Orbimed Advisors LLC. has 13.82 million shares which valued 168.5 million. On Mar 30, 2020, RA Capital Management, L.P. owned 3.24 million shares which valued at 39.5 million. On Mar 30, 2020, EcoR1 Capital, LLC has a total of 2.25 million shares which valued at 27.41 million. In the end, EcoR1 Capital, LLC have 6.57% shares outstanding of Prevail Therapeutics Inc. (PRVL) on Mar 30, 2020. The insider ownership moved to 18.19% and institutional holding shifted to 86.80%.
The company posted an EPS (TTM) of -3.13. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.59, while -0.58 EPS posted a year ago period. Analyst Estimated EPS for PRVL published in the report was -$0.66 – -$0.54 during the same period. Comparing with last year, the average estimated EPS was -0.58 which is lower than -0.56 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for PRVL rise 2.97% for period of 200 days. SMA for 50 days was -2.65% which is showing red signal, while SMA-20 was 0.95%. The moving average value for Prevail Therapeutics Inc. (PRVL) is 15.47 and 15.51 for 200 and 50 days respectively.